Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Stem Cell Res Ther ; 9(1): 34, 2018 02 12.
Article in English | MEDLINE | ID: mdl-29433559

ABSTRACT

CXCR4 was the first receptor identified for CXCL12, but a second receptor, CXCR7, has also been described and its function in hematopoietic cells remains unknown. By inhibition of CXCR4 and/or CXCR7, we showed that CXCR7 participates in normal CD34+ and U937 cell migration and prevents downregulation of CXCR4 by CXCL12 stimulation. In addition, CXCR7 contributes to homing of acute myeloid leukemia and normal progenitor cells to the bone marrow and spleen of NOD/SCID mice. In summary, this study shows an essential role of CXCR7, together with CXCR4, in the control of normal and malignant hematopoietic cell migration and homing induced by CXCL12.


Subject(s)
Cell Movement , Chemokine CXCL12/metabolism , Hematopoietic Stem Cells/metabolism , Leukemia, Myeloid, Acute/metabolism , Neoplasm Proteins/metabolism , Neoplastic Stem Cells/metabolism , Receptors, CXCR/metabolism , Animals , Hematopoietic Stem Cells/pathology , Heterografts , Humans , Leukemia, Myeloid, Acute/pathology , Mice , Mice, Nude , Mice, SCID , Neoplasm Transplantation , Neoplastic Stem Cells/pathology , U937 Cells
2.
PLoS One ; 9(1): e85926, 2014.
Article in English | MEDLINE | ID: mdl-24497931

ABSTRACT

Recently, a novel CXCL12-binding receptor, has been identified. This CXCL12-binding receptor commonly known as CXCR7 (CXC chemokine receptor 7), has lately, based on a novel nomenclature, has received the name ACKR3 (atypical chemokine receptor 3). In this study, we aimed to investigate the expression of CXCR7 in leukemic cells, as well as its participation in CXCL12 response. Interesting, we clearly demonstrated that CXCR7 is highly expressed in acute lymphoid leukemic cells compared with myeloid or normal hematopoietic cells and that CXCR7 contributed to T-acute lymphoid leukemic cell migration induced by CXCL12. Moreover, we showed that the cellular location of CXCR7 varied among T-lymphoid cells and this finding may be related to their migration capacity. Finally, we hypothesized that CXCR7 potentiates CXCR4 response and may contribute to the maintenance of leukemia by initiating cell recruitment to bone marrow niches that were once occupied by normal hematopoietic stem cells.


Subject(s)
Chemokine CXCL12/pharmacology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Receptors, CXCR4/metabolism , Receptors, CXCR/metabolism , Adult , Aged , Aged, 80 and over , Benzylamines , Blotting, Western , Bone Marrow/metabolism , Cell Line, Tumor , Cell Movement/drug effects , Cell Movement/genetics , Cyclams , Female , Flow Cytometry , Gene Expression Regulation, Leukemic/drug effects , Heterocyclic Compounds/pharmacology , Humans , Jurkat Cells , K562 Cells , Leukocytes/metabolism , Male , Middle Aged , Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , RNA Interference , Receptors, CXCR/blood , Receptors, CXCR/genetics , Receptors, CXCR4/antagonists & inhibitors , Reverse Transcriptase Polymerase Chain Reaction , U937 Cells , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...